Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for alcohol withdrawal and relapse prevention
2015-004463-37Phase 3Completed
- Sponsor
- St. Olavs University Hospital
- Start
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in alcohol dependence and alcohol withdrawal syndrome (AWS) comparing Syntocinon with Placebo (2 arms). Primary endpoints: Oxazepam use during detoxification, Time to relapse and 1 more. Started Jan 2016; status: completed.
02
Drugs
oxytocin
03
Conditions
alcohol dependencealcohol withdrawal syndrome (AWS)
Beyond the preview
Go deeper on 2015-004463-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004463-37.